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E3 ligases: historically a two-party system
Ubiquitination  is  the  process  by  which  proteins  are 
selectively  targeted  for  a  variety  of  cellular  fates.  This 
post-translational modification is carried out by a trio of 
enzymes:  an  E1  ubiquitin-activating  enzyme,  an  E2 
ubiquitin-conjugating  enzyme,  and  an  E3  ubiquitin 
ligase. In most cases, E3 ubiquitin ligases assume the role 
of  transferring  activated  ubiquitin  from  a  restricted 
cohort of E2s to specific substrates. In a given genome, 
putative E3s greatly outnumber E2s, underscoring their 
role in substrate selection. For example, in humans, there 
are over 600 E3 ubiquitin ligases and fewer than 40 E2s 
[1]. On the basis of their mechanism and structure, E3 
ligases have historically been classified into two families, 
the  HECT-  and  RING/UBOX-type  ligases  (Figure  1). 
Recently  we  determined  that  Ariadne,  the  defining 
member  of  a  subclass  of  RING-containing  E3  ligases 
known  as  RING-between-RINGs  (RBRs),  blurs  the  line 
between RING and HECT-type E3s.
Eukaryotic E3 ubiquitin ligases are generally identified 
by the presence of either a HECT or a RING domain. The 
features of each type of domain are well defined and are 
readily predictable by primary sequence analysis. RINGs 
are  characterized  by  a  regular  spacing  of  conserved 
cysteines and histidines which bind two Zn2+ ions that 
stabilize the overall structure of this domain, allowing for 
recognition and activation of E2 Ub-conjugating enzymes 
[2].  HECT  domains  are  identified  on  the  basis  of  their 
similarity to the founding member of the family, E6AP. In 
contrast  to  RING  domains,  which  can  occur  at  any 
position  within  a  given  protein,  all  known  HECT 
domains are found at the carboxy-terminal end of their 
respective  proteins.  The  HECT  domain  has  a  bilobal 
structure:  the  lobe  at  the  amino-terminal  end  of  the 
domain  (the  N-lobe)  serves  as  the  E2-binding  domain, 
and  the  lobe  at  the  carboxyl  terminus  (the  C-lobe) 
contains the catalytic cysteine.
There are two general mechanisms by which the ultimate 
substrate-ubiquitin  isopeptide  adduct  is  formed.  An 
essential difference between the two mechanisms is the 
location  of  activated  ubiquitin  at  the  final  transfer  step 
(Figure  1a).  In  reactions  involving  RING/UBOX-type 
ligases, the ubiquitin is attached to an E2 to form an E2~Ub 
thioester conjugate, and the E3 binds both substrate and 
the  E2~Ub  simultaneously  to  promote  the  aminolysis 
reaction in which ubiquitin is transferred to a lysine on a 
substrate.  By  an  as  yet  undetermined  mechanism,  E3 
binding  enhances  the  reactivity  of  the  E2~Ub  thioester 
bond to allow for aminolysis [3,4]. Catalytic residues have 
not been identified for RING/UBOX type ligases and are 
presumed  not  to  exist.  In  reactions  involving  HECT  E3s, 
ubiquitin is transferred from an E2~Ub to form an E3~Ub 
thioester  conjugate  and  the  final  transfer  step  occurs 
directly from the E3 active site to a substrate lysine. Thus, 
the two mechanisms differ in terms of the identity of the 
active site that is responsible for the aminolysis: it is the E2 
active site in RING/UBOX-catalyzed reactions and it is the 
E3 active site in HECT-catalyzed reactions. Substrates may 
be  mono-ubiquitinated  at  one  or  more  sites;  or  poly-
ubiquitin chains may be attached to them. Poly-ubiquitin 
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their distinct linkages, and named K48, K63, K11, K27, K29, 
K33, and K6 chains according to the lysine residue through 
which the ubiquitins are linked to one another; or linear 
chains when the linkage is between the carboxyl terminus 
of one ubiquitin and the amino terminus of the next
Because the E2 active site is responsible for aminolysis 
in  RING/UBOX-catalyzed  reactions,  it  follows  that  the 
product  produced  by  RING/UBOX-type  ligases,  be  it 
mono-ubiquitination  or  a  poly-ubiquitin  chain  of  a 
specific  topology,  is  determined  in  large  part  by  the 
identity of the E2 involved in the reaction. A RING-type 
Figure 1. RING and HECT-type mechanisms of ubiquitin transfer. (a) On the left, a RING E3 ligase (blue) is shown bound to a ubiquitin-
conjugated E2, from which the ubiquitin is transferred to a lysine on the substrate. On the right, a HECT E3 ligase (orange) is shown bound to a 
ubiquitin-conjugated E2, from which ubiquitin is first transferred to the active-site cysteine of the E3, and is then transferred to a lysine on the 
substrate bound to the E3 (lower panel). (b) Proposed mechanism for RBR ubiquitin transfer. RBR ligases combine features of both RING- and HECT-
type ligases. The ubiquitin-conjugated E2 binds to the RING1 domain of the RBR E3 ligase. The ubiquitin is then transferred from the E2 to the E3 
RING2 domain from which it is transferred to the substrate.
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Page 2 of 8E3 that can bind a diverse set of E2s has the potential to 
produce several distinct types of ubiquitination products. 
This phenomenon has been demonstrated for a growing 
number  of  RING-type  ligases  such  as  BRCA1/BARD1 
and the APC, which can produce poly-ubiquitin of K63 
and K48 linkages, as well as mono-ubiquitin, depending 
on the E2 [5,6]. In contrast, it is the identity of the HECT-
type  E3  itself  that  determines  the  type  of  ubiquitin 
modifications conferred on substrates by this class of E3 
ligases, and residues in the active-site-containing C-lobe 
have been shown to determine the type of ubiquitination 
signal generated by HECT-type E3s [7].
RBR E3s: Reaching across the aisle
RBR  E3s  were  originally  identified  by  virtue  of  their 
RING  domains,  but  the  presence  of  two  additional 
domains, IBR and RING2, define them as a subclass [8,9]. 
RBR-type ligases are defined by a trio of closely spaced 
domains:  1)  a  canonical  amino-terminal  RING  domain, 
dubbed  RING1,  2)  an  in-between  RING  domain  (IBR), 
and  3)  a  domain  named  RING2  [10].  As  in  the  case  of 
canonical  RING  domains,  RBR  domains  are  not  limited 
to any particular location within the proteins that contain 
them.  Although  RING1  domain  sequences  follow  the 
cysteine  and  histidine  patterns  typical  of  RINGs  from 
other E3 ligase families, the IBR and RING2 domain do 
not,  and  these  two  domains  are  unique  to  RBR-type 
proteins. RBR E3 ligases are found throughout eukaryotes 
with two members in yeast and thirteen in human [10].
Despite their strong persistence throughout evolution, 
most  RBR  E3s  are  not  well  understood,  and  their 
substrates and E2 partners are poorly defined. Members 
of this E3 family mediate diverse processes that include 
the regulation of translation and the activation of NF-κB 
signaling, among others [11,12]. The most studied RBR 
E3 is Parkin, because of its association with Parkinson’s 
disease  [13]. The  list  of  Parkin  substrates  continues  to 
grow,  although  it  is  not  clear  which  are  critical  for 
understanding the death of dopaminergic neurons, the 
hallmark  of  Parkinson’s  disease.  The  first  substrates 
reported  for  Parkin  were  α-synuclein,  Pael-R,  and 
CDCrel-1,  all  of  which  accumulate  in  patients  with 
heritable Parkinson’s disease [14,15,16]. These substrates 
suggest a role for Parkin in the clearance of misfolded or 
aggregation-prone  proteins.  Additionally,  Parkin  is 
recruited to mitochondria where it is thought to regulate 
turnover  of  damaged  mitochondria.  Proteins  that 
regulate  mitochondrial  morphology,  mitofusin-1  and 
mitofusin-2,  are  substrates  of  Parkin  ubiquitination 
[17,18].
Several  RBR  ligases  have  roles  in  regulating  immune 
signaling.  Overexpression  of  RNF216  (TRIAD3,  ZIN) 
enhances the degradation of specific Toll-like receptors, 
with  co-ordinate  down-regulation  of  Toll-like  receptor 
signaling  [19].  RNF216  may  function  to  attenuate  the 
host response to viral invasion, as RNF216 ubiquitinates 
TRAF3,  a  potentiator  of  the  anti-viral  response,  and 
targets  it  for  proteasomal  degradation  [20].  The  RBR 
proteins  Rbck1  (HOIL-1)  and  RNF31  (HOIP)  form  a 
heterodimeric E3 ligase that function together with the 
protein  SHARPIN  to  generate  linear  ubiquitin  chains 
[21,22]. Linearly-linked poly-ubiquitin chains specifically 
recruit  components  of  the  NF-κB  signaling  pathway 
including  NEMO  to  promote  the  phosphorylation  and 
subsequent degradation of inhibitors of NF-κB.
Yeast contain two RBR proteins, orthologs for Ariadne 
(ARIH1) and RNF14 (ARA54). It has been suggested that 
the extreme conservation of RBR genes from the earliest 
eukaryotes to human may indicate that these proteins 
assume a housekeeping role [23]. Human RNF14 was first 
identified through a yeast two hybrid screen for proteins 
that bind to the androgen receptor, and is thought to be a 
co-activator  of  androgen  receptor  function  [24].  The 
yeast  ortholog  to  RNF14  may  have  a  function  in  the 
regulation of translation termination [25]. The Drosophila 
protein Ariadne, which was the first member of the RBR 
family to be described, is important for the development 
of  the  fly  nervous  system:  neuronal  differentiation  is 
disrupted in Ariadne mutants because of a failure in axon 
guidance [9]. Ariadne was named after the Greek goddess 
Ariadne, whose thread was said to help guide Theseus 
out of the Minotaur’s labyrinth.
Ariadne and other RBR-type E3s have been presumed 
to  be  RING-like  in  both  structure  and  mechanism 
because of the similarities between RING1 and canonical 
RING  domains.  Unexpectedly,  we  discovered  that  the 
human  RBR  E3  HHARI  (human  homolog  of  Ariadne) 
functions in a way that is analogous to that of a HECT-
type ligase, in that it forms an obligate thioester bond 
with ubiquitin before it is transferred to the substrate [3] 
(Figure  1b).  A  cysteine  in  the  RING2  domain  that  is 
highly conserved among all RBR-type E3s functions like a 
HECT active site cysteine: when this cysteine is mutated 
to  serine,  an  oxy-ester-linked  HHARI~Ub  intermediate 
can  be  trapped.  Mutation  of  the  analogous  cysteine 
residue  (C431)  in  RING2  of  Parkin  disrupts  ubiquitin 
transfer  mediated  by  this  RBR  E3,  suggesting  that  this 
mode  of  ubiquitin  transfer  is  a  general  feature  of  RBR 
E3s. Because they contain both a RING-type E2-binding 
domain at their amino-terminal end and an active-site-
containing  domain  at  their  carboxy-terminal  end,  we 
proposed  that  RBRs  can  be  thought  of  as  RING-HECT 
hybrids.
Domain and structural analysis of RBRs
To  date,  structural  insights  into  the  RBR  ligase 
supradomain  are  limited  to  structures  solved  for 
individual component domains: there are two structures 
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Page 3 of 8of IBR domains, and one structure each of a RING1 and 
RING2  domain  [26,27]  [PDB  ID  1WIM,  PDB  ID  2CT7]. 
The dearth of structural information is probably due to 
the difficulty of expressing and purifying these proteins 
in  large  amounts.  With  such  a  small  sampling,  it  is 
unclear whether these structures will be representative of 
the entire family of RBR ligases. However, the sequence 
similarity of these domains among human members of 
the  RBR  ligase  family  suggests  we  may  expect  to  see 
similar structures.
Though  limited,  the  available  structures  do  provide 
some  functional  insights. The  structure  of  the  RNF144 
RING1 is similar to that of other RING-type E3s such as 
BRCA1,  with  the  E2-binding  interface  readily  apparent 
(PDB  ID  1WIM,  Figure  2).  E2-E3  disrupting  mutations 
that  are  structurally  analogous  to  those  in  bona  fide 
RING-type E3s abrogate the binding of the E2 UbcH7 to 
HHARI [5,28,29].  Although the E2-E3 binding interactions 
of RBR E3 ligases seem to be analogous to those of the 
RING  E3  ligases,  the  functional  consequence  of  the 
interaction is not. Whereas binding of the BRCA1/BARD1 
RING domain leads to a significant enhancement of the 
thioester reactivity of the E2~Ub conjugate (in this case 
UbcH5c~Ub)  towards  lysine,  no  enhancement  of  E2 
reactivity was detected for a construct composed of the 
RING1  and  IBR  domains  of  HHARI  [3].  Thus,  although 
the  RING1  domain  of  HHARI  serves  as  an  E2-binding 
domain, it lacks the catalytic capacity of other canonical 
RING domains. Whether this is a general feature of the 
RING1 domains of RBRs remains to be tested experimentally.
The function of the IBR domains of RBR ligases is even 
less clear. The IBR domains of Parkin and RNF31 (HOIP) 
are structurally sparse outside of the two Zn2+ binding-
centers (Figure 3) [26]. Shaw and colleagues noted that 
the amino- and carboxy-termini of the IBR domain are 
close to one another and may therefore serve to bring the 
RING1  and  RING2  domains  together  [26].  Such  a 
function would be analogous to that of the flexible linker 
found between the amino-lobe and the carboxy-lobe in 
HECT-type  E3s,  which  allows  conformational  changes 
essential  for  E3  activity.  If  so,  one  would  predict  that 
mutations that either reduce the flexibility of the putative 
linker region or change the orientation of the two RING 
domains would disrupt ubiquitin transfer, as reported for 
the  HECT  ligase  WWP1  [30].  However,  the  structural 
conservation  of  the  IBRs  in  terms  of  Zn2+-binding 
residues, number of amino acids, and the fact that this 
domain is found almost exclusively in RBR E3s, suggest 
that the domain is unlikely to serve merely as an elaborate 
linker.
Figure 2. RING1 of RBRs maintains features characteristic of canonical RINGs. (a) Structures of RING domains are displayed with Zn2+ 
coordinating residues as yellow sticks and Zn2+ ions displayed as grey spheres. A conserved hydrophobic residue important for E2 binding is shown 
as orange sticks. The structures are (from left to right) the E3 ligase CNOT4 (blue) bound to the E2 UbcH5b (purple) (PDB ID 1UR6) (the E2 active 
site is shown as yellow spheres); the heterodimeric RING E3 ligase BRCA1 (blue)/BARD1 (green) (PDB ID 1JM7); TRAF6 (PDB ID 3HCT); RING1 of 
the RBR E3 RNF144 (PDB ID 1WIM). (b) Multiple sequence alignment of the RING domains of CNOT4, BRCA1, TRAF6, and RNF144. Coloring in the 
multiple sequence alignment corresponds with the colors in the structures, highlighting residues important for Zn2+ coordination and E2 binding. 
Sequences were aligned using CLUSTALW and manually adjusted based on structure [44].
CNOT4:    CPLCMEPLEIDDINFFP-CTCGYQICRFCWHRIRT---DEN---G--LCP--AC
BRCA1:    CPICLELIK-EP--VSTKCDHIF--CKFCMLKLLN---QKK---GPSQCP--LC
TRAF6:    CPICLMALR-EA--VQTPCGHRF--CKACIIKSIR---D-----AGHKCP--VD
RNF144:   CKLCLGEYPVEQMTTIAGCQCIF--CTLCLKQUVELLIK-EGLETAISCPDAAC
(a)
(b)
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active  site  cysteine  clarifies  several  observations  about 
Parkin  activity,  while  raising  new  questions  about  the 
structure and mechanisms of this family of ligases. The 
Parkin  mutation  C431F  gives  rise  to  a  loss-of-function 
phenotype  and  is  associated  with  juvenile  onset 
Parkinson’s  disease,  a  phenotype  that  was  earlier 
attributed  to  structural  destabilization,  under  the 
presumption that C431 was involved in Zn2+ binding [31]. 
More  recent  experiments,  however,  in  which  the 
conserved  cysteines  of  Parkin  were  systematically 
mutated  to  alanine,  showed  that  most  mutants  were 
insoluble  and  mislocalized,  except  the  C431A  mutant, 
suggesting  that  this  residue  is  not  part  of  the  Zn2+ 
coordination  network  of  Parkin  [32].  The  only  RING2 
structure  to  date  is  of  HHARI  RING2  [27]  (Figure  4). 
Unlike  the  RING1  domain,  whose  structure  led  to  the 
notion that the mechanism of the RBR ligases would be 
like  that  of  the  canonical  RING  ligases,  the  HHARI 
RING2 domain structure looks nothing like a canonical 
E2-binding RING: we discuss below the implications of 
this  structural  dissimilarity.  Despite  the  presence  of  six 
well  conserved  cysteines,  the  structure  binds  only  one 
Zn2+ ion, leaving two cysteine residues unliganded [27]. 
We have identified one of the free cysteines, C357, as the 
active  site  cysteine  of  HHARI.  The  single  Zn2+-binding 
site  in  HHARI  RING2  contrasts  with  electrospray  mass 
spectrometry data that predict two Zn2+ ions for Parkin 
RING2 [33]. The coordination of Zn2+ residues in Parkin 
may  well  differ  from  that  of  HHARI,  and  how  this  is 
accomplished  remains  to  be  determined  structurally. 
Rankin  and  colleagues  propose  a  Parkin  RING2  model 
with two Zn2+-binding sites, composed of residues C418, 
C421, C441, C436 and C446, C449, H461, C457 [34]. This 
model  leaves  C431  free  to  form  a  thioester  bond  with 
ubiquitin (Figure 4).
RBR isopeptide catalysis
The  observation  that  RBR  ligases  function  through  a 
HECT-like  mechanism  implies  that  there  are  additional 
residues  near  the  active  site  cysteine  that  facilitate 
isopeptide catalysis with a substrate lysine. However, if 
studies with HECT E3s are any indication, these may be 
difficult to identify. Aside from the active site cysteine, 
few catalytic residues have been identified within HECT 
domain  ligases.  Studies  involving  a  bacterial  HECT-like 
E3,  SopA,  identified  a  conserved  motif  among  HECT 
domain active sites surrounding the active site cysteine, 
LXXShTCfXn  (where  upper  case  letters  indicate 
invariant residues, lower case letters indicate conserved 
residues  and  X  indicates  a  variable  position)  [35]. 
Mutation  of  the  conserved  leucine  or  threonine  to  an 
alanine  decreases  activity  [35].  Removal  of  a  highly 
conserved phenylalanine in the carboxy-terminal tail of 
Figure 3. Conservation of the IBR domain. (a) Structures of IBR domains solved to date from RNF31 (left) (PDB ID 2CT7) and Parkin (right) 
(PDB ID 2JMO). (b) Multiple sequence alignment of the IBR domain from human RBR ligases. Residue numbers are shown at the beginning of 
the alignment. Sequences were aligned using CLUSTALW [44]. Swiss-Prot numbers for sequences used in multiple sequence alignments are as 
follows: Cullin-9: Q81WT3, Parkin: O60260, ANKIB1: Q9P2G1, ARIH1: Q9Y4X5, ARIH2: O95376, RBCK1: Q9BYM8, RNF144A: P50876, RNF144B:Q7Z419, 
RNF19A:Q9NV58, RNF19B: Q6ZMZ0, RNF216: Q9NWF9, RNF14: Q9UBS8, and RNF31: Q96EP0.
RNF144B_[IBR]   QLYQRLKFEREVH--LDPYRTWCPVA-DCQTVCPVASSDPGQPVLVECP------------SCH--LKFCSCC-KDAW---HAEVSC
RNF144A_[IBR]   QRYKKLQFEREVL--FDPCRTWCPAS-TCQAVCQLQDVGLQTPQPVQCK------------ACR--MEFCSTC-KASW---HPGQGC
Cullin-9_[IBR]  SKYEKALLRGYVE--SCSNLTWCTNPQGCDRILCRQGLGCGT---TCS-------------KCG--WASCFNCSFPEA---HYPASC
ANKIB1_[IBR]    KRYLQFDIKAFVE--NNPAIKWCPTP-GCDRAVRLTKQGSNT---SGSDTLSFPLLRAPAVDCGKGHLFCWEC-LGEA---HEPCDC
ARIH2_[IBR]     -KYRRYLFRDYVE--SHYQLQLCPGA-DCPMVIRVQEPRARR---VQCN------------RCN--EVFCFKC-RQMY---HAPTDC
ARIH1[IBR]      LKYQHLITNSFVE--CNRLLKWCPAP-DCHHVVKVQYPDAKP---VRC-------------KCG--RQFCFNC-GENW---HDPVKC
RNF19B_[IBR]    HKYEEFMLRRYLA--SDPDCRWCPAP-DCGYAVIAYGCASCP--KLTCER----------EGCQ--TEFCYHC-KQIW---HPNQTC
RNF19A_[IBR]    EKYEEFMLRRWLV--ADPDCRWCPAP-DCGYAVIAFGCASCP--KLTCGR----------EGCG--TEFCYHC-KQIW---HPNQTC
RNF14_[IBR]     ARYDRLLLQSSLD--LMADVVYCPRP--CCQLPVMQEPGCTMG---ICS------------SCN--FAFCTLC-RLTY---HGVSPC
Parkin_IBR      NRYQQYGAEECVL--QMGG-VLCPRP-GCG-AGLLPEPDQRK---VTCEG-------GNGLGCG--FAFCREC-KEAY---HEG-EC
RNF31_[IBR1_deg ALFHKKLTEGVLM--RDPKFLWCAQ---CSFGFIYEREQLEA----TCP------------QCH--QTFCVRC-KRQWEEQHRGRSC
RBCK1[HOIL-1]_I ------ENRSAFS--YH-----CKTP-DCKGWCFFEDDVNEF----TCP------------VCF--HVNCLLC--KAI---HEQMNC
RNF216_[IBR]    YKYYERKAEEEVAAAYADELVRCPS---CSFPALLDSDVKRF----SCPN----------PHCR--KETCRKC-QGLWK-EHNGLTC
        - -l----v---- ----wCp-p--C-----v---- - ---------C-----fC--C-k--w---H----C
RNF144B _101
RNF144A _91
Cullin-9 _2140
ANK1B1 _402
ARIH2 _208
ARIH1 _256
RNF19B _186
RNF19A _199
RNF14 _289
Parkin _313
RNF31 _779
RBCK1 _362
RNF216 _583
* * * * * * * *
RNF31 Parkin
(b)
(a)
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to modify lysines on substrates, but does not interfere 
with  transthiolation  from  E2  to  the  HECT  active  site 
cysteine  [36]. Whether  the  conserved  phenylalanine  in 
HECT domains plays a direct role in catalysis remains to 
be seen. It is not clear if RBR-type E3s will use a similar 
mechanism for function. The lack of similarity between 
HECT E3 C-lobes and RBR RING2s at the sequence level 
suggests it will be challenging to identify residues that are 
important  for  isopeptide  catalysis  on  the  basis  of  our 
current knowledge. Residues around the RBR active site 
cysteine do not follow the LXXShTCfXn motif, and as the 
role of the carboxy-terminal phenylalanine in HECT-type 
ligases is not well understood, it is impossible to know if 
RBR-type  ligases  have  residues  that  fulfill  a  similar 
function. The possibility remains that residues in other 
domains  of  the  RBR  may  contribute  to  the  activity  of 
RING2.  Structural  and  biochemical  characterization  of 
RING2 in context of the RING1 and IBR domains may be 
key to future progress in this respect.
Like  HECT  ligases,  the  ubiquitination  products 
generated by RBRs are independent of E2 identity and are 
likely to be an intrinsic property of each RBR E3. To date, 
polyubiquitin  chains  with  linear,  Lys48,  and  Lys63 
linkages,  multiple  mono-ubiquitination,  and  mono-
ubiquitination have all been reported as products of RBR 
ligases [37,38,39,40,41]. Although Parkin itself has been 
reported to form many types of products, a recent study 
suggests that Parkin products can be influenced by the 
fusion  of  artificial  molecular  tags,  or  truncation  of 
constructs, so previous results should be viewed in this 
light  [42].  The  RBR  proteins  RBCK1  (HOIL-1)  and 
RNF31 (HOIP) form a complex known as LUBAC (Linear 
Ubiquitin  Assembly  Complex)  and  produce  linear 
polyubiquitin  chains  with  the  human  E2s  UbcH7, 
UbcH5,  and  Ube2k  [37].  To  date,  no  HECT-type  or 
canonical  RING-type  E3s  have  been  reported  to  build 
linear poly-ubiquitin chains, suggesting that this property 
may be distinctive of RBR E3s. Future studies aimed at 
understanding the determinants within RBRs that specify 
the type of product generated are needed to further our 
understanding of RBR mechanism and function.
Unanswered questions
The distinct features of the RBRs indicate that attempts 
to  extrapolate  from  knowledge  of  the  other  better 
characterized classes of E3 ligases are likely to fail. This 
opens  a  host  of  unanswered  questions  regarding  RBR 
function.  Which  E2s  work  to  transfer  ubiquitin  to  RBR 
E3s and what are the determinants and features of this 
step? To  date,  the  cohort  of  E2s  identified  as  working 
with RBR-type ligases most often includes the E2s UbcH7 
and  UbcH8  [10].  UbcH7  (and  probably  UbcH8  by 
analogy) can only transfer ubiquitin via a transthiolation 
reaction and are therefore specialized E2s for HECT-type 
transfer  mechanisms  [3].  Even  though  it  is  a  RING 
domain (RING1) of RBRs that binds E2s directly, the RBR 
version of the domain appears to bind E2s with higher 
affinity than do canonical E3 RING domains: complexes 
of  UbcH7  and  RING1s  can  be  identified  by  pull-down 
and co-immunoprecipitation experiments [28]. What are 
the  determinants  and  consequences  of  stronger  E2 
Figure 4. Comparison of HHARI RING2 with Parkin RING2. (a) Multiple sequence alignment of HHARI RING2 and Parkin RING2. Zn2+-liganding 
residues determined structurally for HHARI RING2 are denoted in yellow. Potential additional Zn2+ coordinating residues in Parkin as proposed by 
Rankin et al. [34] are highlighted in red. The active site cysteine is denoted by a double dagger. (b) The structure of HHARI RING2 displays Zn2+-
liganding residues as yellow sticks. The active site cysteine is shown as orange sticks (PDB ID 1WD2). Sequences were aligned using CLUSTALW [44].
Parkin_418  CPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV- 
ARIH1_ 344  CPKCHVTIEKDGGCNHMVCRNQNCKAEFCWVCLGPWEP--HGSAWYNCN 
  
‡
(a)
(b)
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them  preferred  RBR-binding  partners?  How  do  RBR 
ligases recognize and bind substrates? Substrate binding 
has been reported for almost every domain from RING1 
to  RING2  and  in  regions  outside  the  RBR  domain  [10]. 
Given  the  variety  of  substrate  binding  modes 
documented  for  other  families  of  E3  ligases,  it  seems 
unlikely that RBR ligases will have a common mechanism 
for  substrate  binding.  The  RBR  ligase  Parkin  has  been 
found  to  associate  with  SCF-type  ubiquitin  ligases, 
raising the possibility that adapter proteins may provide 
substrate specificity for a subset of these E3s [43]. Future 
studies  informed  by  the  new  insights  regarding  the 
distinctive mode of action for RBR E3s will no doubt shed 
light  on  these  and  other  questions  surrounding  RBR 
function.
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